MULTICENTRIC LYMPHADENOPATHY
MULTICENTRIC LYMPHADENOPATHY:
Imaging (e.g. CT scan) should be performed to determine the locations of enlarged nodes and, if possible, [F]-fludeoxyglucose positron emission tomography should be performed to identify [F]-fludeoxyglucose-avid nodes for biopsy, and to distinguish iMCD from lymphoma.1
© 2021 EUSA Pharma
Date of prep: November 2021 GL-SIL-2100101
This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.
© 2021 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ